Breaking News

Holland Takes 2-0 Lead Over Brazil in World Cup Runner-up Match
Tweet TWEET

Biotech Companies Report Quarterly Results - Research Report on Biogen Idec, Alexion, Medivation, BioMarin, and Dyax

 Biotech Companies Report Quarterly Results - Research Report on Biogen Idec,
                   Alexion, Medivation, BioMarin, and Dyax

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, October 31, 2013

NEW YORK, October 31, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Biogen
Idec Inc. (NASDAQ: BIIB), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN),
Medivation, Inc. (NASDAQ: MDVN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN),
and Dyax Corp. (NASDAQ: DYAX). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Biogen Idec Inc. Research Report

On October 28, 2013, Biogen Idec Inc. (Biogen Idec) released its Q3 2013
results. Biogen Idec registered Q3 2013 revenues of $1.8 billion, up 31.9%
YoY. According to Biogen Idec, revenues were primarily driven by TECFIDERA
(dimethyl fumarate), which is now the leading oral MS therapy in the US and
accounted for $286 million in Q3 2013 revenues. Net income attributable to the
Company was $487.6 million or $2.05 per diluted share, compared to $398.4
million or $1.67 per diluted share in Q3 2012. The Full Research Report on
Biogen Idec Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/b95b_BIIB]

--

Alexion Pharmaceuticals, Inc. Research Report

On October 24, 2013, Alexion Pharmaceuticals, Inc. (Alexion) released its Q3
2013 results. Alexion registered net product sales of $400.4 million, compared
to $294.1 million in Q3 2012. Alexion posted net income of $93.8 million or
$0.47 per diluted share, compared to $294.1 million or $0.46 per diluted share
in Q3 2012. Commenting on the results, Leonard Bell, M.D., CEO of Alexion,
said, "In the third quarter, we continued our strong and ongoing global
performance with Soliris in PNH and were pleased to provide Soliris to a
steadily growing number of new patients with aHUS in the United States as well
as an increasing number of patients with aHUS in Europe. In addition, we were
pleased to receive our aHUS approval in Japan." Bell continued, "Key pipeline
initiatives, including our asfotase alfa program in HPP, our Soliris programs
in kidney transplant and our cPMP replacement therapy program, reached new
milestones in Q3. In Q4, we are further expanding our commercial and clinical
initiatives as we prepare for further growth in 2014." The Full Research
Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.AnalystsCorner.com/r/full_research_report/4619_ALXN]

--

Medivation, Inc. Research Report

On October 28, 2013, Medivation, Inc. (Medivation) announced that it will
release its Q3 2013 results after the markets close on November 12, 2013.
Medivation reported that the release will be followed by its Q3 2013
conference call on the same day at 4:30 p.m. ET. The Company stated that the
live conference will be accessible through its Investor Relations website. The
Full Research Report on Medivation, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.AnalystsCorner.com/r/full_research_report/4277_MDVN]

--

BioMarin Pharmaceutical Inc. Research Report

On October 24, 2013, BioMarin Pharmaceutical Inc. (BioMarin) released its Q3
2013 results. BioMarin registered total revenues of $136.9 million, an
increase of 6.9% YoY. The Company posted net loss of $53.0 million in Q3 2013,
compared to net loss of $5.4 million in Q3 2012. BioMarin reported diluted
loss per share of $0.38 in Q3 2013, compared to diluted loss per share of
$0.04 in Q3 2012. Jean-Jacques Bienaimé, CEO of BioMarin, stated, "During the
third quarter we saw continued steady growth of our development pipeline. We
announced the advancement of two important programs, the decision to advance
BMN 673 for the treatment of gBRCA breast cancer into Phase 3 and the
initiation of a Phase 1/2 trial of BMN 190 for the treatment of Batten
Disease." Bienaimé continued, "The next major inflection point for the company
is the potential market approval of Vimizim in the U.S. and Europe. We have
been working diligently to prepare for the launch of this drug and look
forward to the Advisory Committee meeting November 19 and potential CHMP
opinion, which we expect near the end of the year or early 2014." The Full
Research Report on BioMarin Pharmaceutical Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.AnalystsCorner.com/r/full_research_report/9b6c_BMRN]

--

Dyax Corp. Research Report

On October 22, 2013, Dyax Corp. (Dyax) released its Q3 2013 results. Dyax
registered total revenues of $13.7 million in Q3 2013, up 4.5% YoY. The
Company posted net loss attributable to common shareholders of $6.2 million or
$0.06 per diluted share in Q3 2013, compared to net loss attributable to
common shareholders of $5.2 million or $0.05 per diluted share in Q3 2012.
Gustav Christensen, President and CEO of Dyax, commented, "Dyax saw a number
of important milestones in the third quarter, including growth in the KALBITOR
business and successful initiation of the clinical program for DX-2930, a
wholly-owned product candidate currently in development for potential
prophylactic use in HAE." Christensen added, "Additionally, there were a
number of positive Phase 3 data readouts from LFRP candidates, as well as the
completion of marketing applications in the U.S. and Europe for one of these
candidates, ramucirumab, for second-line advanced gastric cancer." The Full
Research Report on Dyax Corp. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/58ae_DYAX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas : +1-310-496-8071 (North America)